Aveo Pharmaceuticals' full Phase III Tivo-3 data for tivozanib in an oral presentation on Saturday "showed clear advantage" for progression-free survival, overall response rate and safety, but the "immature" overall survival data show a hazard ratio of 1.12, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst believes that with more patients still on tivozanib, the hazard ratio could slip below 1.0 and meet the FDA filing requirement. He recommends buying shares of Aveo on weakness and keeps an Overweight rating on the name with a $3 price target.